EGFR and metabolic dysfunction-associated steatotic liver disease: In addition, toralactone and quinizarin differentially bound EGFR to form three (MET-793, GLN-791, and LEU-718) and two (MET-793 and GLN-791) hydrogen bonds, respectively, suggesting that toralactone and quinizarin are the main active ingredients of CSEE in the treatment of NAFLD.